Genentech has announced that tiragolumab, a novel cancer immunotherapy designed to bind to T cell immunoreceptor with Ig and ITIM domains (TIGIT), has been granted Breakthrough Therapy Designation (BTD) by the FDA, in combination with Tecentriq (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression with no EGFR or ALK genomic tumour aberrations.
Ook interessant voor je
